Some batches of Durisan hand sanitizer have been previously recalled and in a new update, the company has further expanded the recall. The U.S. Food and Drug Administration (FDA) explained that the move was due to the fact that the affected hand sanitizers were contaminated with a type of bacteria that could infect the users.
The expanded recall announcement
Based on the FDA’s recall notice that was posted on Tuesday, May 18, Durisan Sanit Technologies updated the recall for its anti-microbial hand sanitizer products. Now, the batches of products to be recalled were expanded to add those that were manufactured after April 10, 2019, and have not expired yet.
The company made the decision because the affected bottles were said to have been contaminated with common bacteria called Burkholderia contaminans. People infected may not experience reactions but for others, they may suffer from more serious effects once the bacteria enter their bloodstream through scrapes or wounds after using the hand sanitizer.
An infection could result from this, as per the FDA. The agency also warned that people with weaker immune systems are more susceptible to infection so the use of the contaminated hand sanitizer is risky.
Other information of the recalled lots
Fox Business mentioned that as per the Centers for Disease Control and Prevention (CDC), Burkholderia cepacia is found in water and soil. This bacteria may also be a little complicated to treat because it is said to be usually resistant to common antibiotics.
In any case, the recalled Durisan hand sanitizer includes 47 lots of the products. These covered the ones packed in various bottle sizes of 18 ml credit cards, 118 ml, 236 ml, 300 ml and 500 ml. The wall-mounted dispensers that use 1000 ml bottles are also included.
Fortunately, there is no report of adverse reactions yet or complaints from customers regarding the contaminated Durisan hand sanitizer. With the voluntary recall of its maker, the FDA said that distributors and retailers were already notified too.
“Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product,” the FDA wrote in the expanded recall announcement. “Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.”


Australia’s Economic Growth Slows in Q3 Despite Strong Investment Activity
Dollar Holds Steady as Markets Shift Focus to 2026 Rate Cut Expectations
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves
Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market
IMF Deputy Dan Katz Visits China as Key Economic Review Nears
Dollar Slides to Five-Week Low as Asian Stocks Struggle and Markets Bet on Fed Rate Cut
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature
U.S. Futures Steady as Rate-Cut Bets Rise on Soft Labor Data
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 



